Nixon Peabody Trust Co. Has $6.88 Million Stake in Elevance Health, Inc. $ELV

Posted by Brian Himes on Jul 4th, 2026

Nixon Peabody Trust Co. raised its holdings in Elevance Health, Inc. (NYSE:ELV – Free Report) by 7.3% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 23,498 shares of the company’s stock after purchasing an additional 1,608 shares during the quarter. Nixon Peabody Trust Co.’s holdings in Elevance Health were worth $6,879,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of ELV. Murphy Middleton Hinkle & Parker Inc. bought a new position in shares of Elevance Health in the fourth quarter valued at about $5,941,000. Bright Rock Capital Management LLC bought a new stake in Elevance Health during the 4th quarter worth about $7,362,000. Prana Capital Management LP increased its position in Elevance Health by 798.9% in the 3rd quarter. Prana Capital Management LP now owns 51,633 shares of the company’s stock valued at $16,684,000 after acquiring an additional 45,889 shares in the last quarter. CIBC Bancorp USA Inc. acquired a new stake in Elevance Health in the 3rd quarter valued at about $10,047,000. Finally, Loews Corp raised its stake in shares of Elevance Health by 107.5% in the third quarter. Loews Corp now owns 110,000 shares of the company’s stock worth $35,543,000 after acquiring an additional 57,000 shares during the last quarter. Institutional investors and hedge funds own 89.24% of the company’s stock.

Insider Transactions at Elevance Health

In other Elevance Health news, Director Robert L. Dixon, Jr. sold 151 shares of Elevance Health stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $401.77, for a total transaction of $60,667.27. Following the completion of the sale, the director owned 10,734 shares of the company’s stock, valued at approximately $4,312,599.18. The trade was a 1.39% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.34% of the company’s stock.

Elevance Health Stock Performance

Elevance Health stock opened at $416.97 on Friday. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.70. Elevance Health, Inc. has a 1 year low of $273.71 and a 1 year high of $427.19. The company has a market cap of $90.55 billion, a PE ratio of 17.74, a PEG ratio of 2.37 and a beta of 0.67. The company’s 50-day moving average is $391.29 and its two-hundred day moving average is $351.14.

Elevance Health (NYSE:ELV – Get Free Report) last issued its earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.74 by $1.84. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The company had revenue of $49.49 billion for the quarter, compared to analyst estimates of $48.21 billion. During the same quarter last year, the firm earned $11.97 EPS. The company’s revenue for the quarter was up 1.5% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Equities analysts anticipate that Elevance Health, Inc. will post 26.86 earnings per share for the current year.

Elevance Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 25th. Shareholders of record on Wednesday, June 10th were paid a $1.72 dividend. The ex-dividend date of this dividend was Wednesday, June 10th. This represents a $6.88 dividend on an annualized basis and a yield of 1.6%. Elevance Health’s dividend payout ratio (DPR) is presently 29.26%.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. Mizuho upped their target price on shares of Elevance Health from $435.00 to $465.00 and gave the stock an “outperform” rating in a research report on Monday, June 8th. Guggenheim raised their price target on shares of Elevance Health from $396.00 to $399.00 and gave the company a “buy” rating in a report on Friday, April 24th. Leerink Partners set a $364.00 price objective on shares of Elevance Health in a research report on Thursday, April 23rd. Truist Financial upped their price objective on Elevance Health from $375.00 to $450.00 and gave the stock a “buy” rating in a report on Monday, June 1st. Finally, Jefferies Financial Group decreased their price objective on Elevance Health from $395.00 to $391.00 and set a “buy” rating on the stock in a research report on Monday, April 20th. Fourteen analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $419.16.

Get Our Latest Analysis on Elevance Health

About Elevance Health

(Free Report)

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.